Show simple item record

dc.contributor.authorOladghaffari, M
dc.contributor.authorIslamian, JP
dc.contributor.authorBaradaran, B
dc.contributor.authorMonfared, AS
dc.date.accessioned2018-08-26T07:41:10Z
dc.date.available2018-08-26T07:41:10Z
dc.date.issued2016
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/47431
dc.description.abstractMLN4924 is an investigational and a newly discovered small molecule that is a potent and selective inhibitor of the NEDD8 (Neural precursor cell-Expressed Developmentally down-regulated 8) Activating Enzyme (NAE), a pivotal regulator of the Cullin Ring Ligases E3 (CRL), which has been implicated recently in DNA damage. MLN4924 effectively inhibits tumour cell growth by inducing all three common types of death, namely apoptosis, autophagy and senescence and it was also reported that the formation of capillary vessels was significantly suppressed by MLN4924.In this review, we are going to highlight the molecular mechanism of MLN4924 in cancer therapy and its pros and cons in cancer therapy.
dc.language.isoEnglish
dc.relation.ispartofJOURNAL OF CHEMOTHERAPY
dc.subjectApoptosis
dc.subjectCancer treatment
dc.subjectMLN4924
dc.subjectNEDD8 activating enzyme
dc.subjectUbiquitin-proteasome system (UPS)
dc.subjectUPS inhibitors (UPSI)
dc.titleMLN4924 therapy as a novel approach in cancer treatment modalities
dc.typeReview
dc.citation.volume28
dc.citation.issue2
dc.citation.spage74
dc.citation.epage82
dc.citation.indexWeb of science
dc.identifier.DOIhttps://doi.org/10.1179/197374947815Y.0000000066


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record